Google
ZBIO — ZENAS BIOPHARMA, INC. COMMON STOCK (Healthcare >> Biotechnology)
ZBIO FAQ
What is ZBIO's ROE?
ZENAS BIOPHARMA, INC. COMMON STOCK reports a Return on Equity (ROE) of -126.60%.
What is ZBIO's dividend yield?
ZENAS BIOPHARMA, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is ZBIO's Deepscope Quality Score?
Deepscope rates ZBIO's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ZBIO?
Deepscope's AI Timing Score for ZBIO is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ZBIO belong to?
ZENAS BIOPHARMA, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 17.47
Price
-0.91
(-4.95%)
Day Change
|
|
|---|
ZBIO, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 17.47 |
| PBV / Sector |
3.27 / 4.63
|
| Earning Per Share | -6.76 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
9.87 M
|
| Average 1W Daily Value |
9.06 M
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:20 |
| Symbol | ZBIO |
| Name | ZENAS BIOPHARMA, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 63.13 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,098.52 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 852 Winter Street, Waltham, MA, United States, 02451
Phone: 857 271 2954
Website: https://zenasbio.com
Employees: 167
Sector: Healthcare >> Biotechnology
Description: Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
